{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T13:18:36Z","timestamp":1792675116543,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013671","name":"Sun Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013671","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","cysticfibrosisjournal.com","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.jcf.2024.09.022","type":"journal-article","created":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T22:25:39Z","timestamp":1729117539000},"page":"47-52","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Development of metabolic syndrome in people with Cystic Fibrosis one year after exposure to elexacaftor-tezacaftor-ivacaftor"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6286-5921","authenticated-orcid":false,"given":"Gregory A.","family":"Ratti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4251-5737","authenticated-orcid":false,"given":"Sasan","family":"Mirfakhraee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0758-3566","authenticated-orcid":false,"given":"Joan","family":"Reisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2807-1110","authenticated-orcid":false,"given":"Leah","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2407-7374","authenticated-orcid":false,"given":"Raksha","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5833-3532","authenticated-orcid":false,"given":"James D.","family":"Finklea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.jcf.2024.09.022_bib0001","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","article-title":"A CFTR potentiator in patients with cystic fibrosis and the G551D mutation","volume":"365","author":"Ramsey","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"19","key":"10.1016\/j.jcf.2024.09.022_bib0002","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.jcf.2024.09.022_bib0003","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.jada.2008.02.020","article-title":"Evidence-based practice recommendations for nutrition-related management of children and adults with cystic fibrosis and pancreatic insufficiency: results of a systematic review","volume":"108","author":"Stallings","year":"2008","journal-title":"J. Am. Diet. Assoc."},{"issue":"10212","key":"10.1016\/j.jcf.2024.09.022_bib0004","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jcf.2024.09.022_bib0005","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1056\/NEJMoa1409547","article-title":"Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR","volume":"373","author":"Wainwright","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.jcf.2024.09.022_bib0006","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jcf.2019.10.004","article-title":"Prevalence and factors associated with overweight and obesity in adults with cystic fibrosis: a single-center analysis","volume":"19","author":"Harindhanavudhi","year":"2020","journal-title":"J. Cyst. Fibros."},{"issue":"Suppl 2","key":"10.1016\/j.jcf.2024.09.022_bib0007","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1016\/j.jcf.2019.08.015","article-title":"Energy balance and obesity in individuals with cystic fibrosis","volume":"18","author":"Litvin","year":"2019","journal-title":"J. Cyst. Fibros."},{"issue":"1","key":"10.1016\/j.jcf.2024.09.022_bib0008","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jcf.2009.09.002","article-title":"Prevalence of dyslipidemia in adults with cystic fibrosis","volume":"9","author":"Rhodes","year":"2010","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.jcf.2024.09.022_bib0009","unstructured":"Foundation, C.F., Cystic fibrosis foundation patient registery annual report. 2021."},{"issue":"6","key":"10.1016\/j.jcf.2024.09.022_bib0010","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.jcf.2008.05.008","article-title":"Microvascular complications in patients with cystic fibrosis-related diabetes (CFRD)","volume":"7","author":"van den Berg","year":"2008","journal-title":"J. Cyst. Fibros."},{"issue":"5","key":"10.1016\/j.jcf.2024.09.022_bib0011","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1111\/j.1440-1843.2010.01771.x","article-title":"Metabolic abnormalities in adults with cystic fibrosis","volume":"15","author":"Georgiopoulou","year":"2010","journal-title":"Respirology."},{"issue":"5","key":"10.1016\/j.jcf.2024.09.022_bib0012","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.jcf.2020.04.004","article-title":"Dyslipidemia is not associated with the development of glucose intolerance or diabetes in cystic fibrosis","volume":"19","author":"Colomba","year":"2020","journal-title":"J. Cyst. Fibros."},{"issue":"6","key":"10.1016\/j.jcf.2024.09.022_bib0013","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1093\/ajcn\/75.6.1005","article-title":"Abnormal lipid concentrations in cystic fibrosis","volume":"75","author":"Figueroa","year":"2002","journal-title":"Am. J. Clin. Nutr."},{"issue":"2","key":"10.1016\/j.jcf.2024.09.022_bib0014","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jcf.2021.11.012","article-title":"Effect of elexacaftor-tezacaftor-ivacaftor on body weight and metabolic parameters in adults with cystic fibrosis","volume":"21","author":"Petersen","year":"2022","journal-title":"J. Cyst. Fibros."},{"issue":"17","key":"10.1016\/j.jcf.2024.09.022_bib0015","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1161\/CIRCULATIONAHA.105.169404","article-title":"Diagnosis and management of the metabolic syndrome: an American heart association\/national heart, lung, and blood institute scientific statement","volume":"112","author":"Grundy","year":"2005","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.jcf.2024.09.022_bib0016","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jacc.2006.09.032","article-title":"Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies","volume":"49","author":"Gami","year":"2007","journal-title":"J. Am. Coll. Cardiol."},{"issue":"12","key":"10.1016\/j.jcf.2024.09.022_bib0017","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.2337\/dc10-1768","article-title":"Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the american diabetes association and a clinical practice guideline of the cystic fibrosis foundation, endorsed by the pediatric endocrine society","volume":"33","author":"Moran","year":"2010","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.jcf.2024.09.022_bib0018","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jcf.2005.09.001","article-title":"Relationship between glycosylated haemoglobin and mean plasma glucose concentration in cystic fibrosis","volume":"5","author":"Brennan","year":"2006","journal-title":"J. Cyst. Fibros."},{"issue":"7","key":"10.1016\/j.jcf.2024.09.022_bib0019","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.2337\/dc17-2419","article-title":"Hemoglobin A(1c) accurately predicts continuous glucose monitoring-derived average glucose in youth and young adults with cystic fibrosis","volume":"41","author":"Chan","year":"2018","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.jcf.2024.09.022_bib0020","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jcf.2022.03.010","article-title":"Obesity in Cystic fibrosis: prevalence, trends and associated factors data from the US cystic fibrosis foundation patient registry","volume":"21","author":"Szentpetery","year":"2022","journal-title":"J. Cyst. Fibros."},{"issue":"Suppl 1","key":"10.1016\/j.jcf.2024.09.022_bib0021","first-page":"S40","article-title":"Overweight and cystic fibrosis: an unexpected challenge","volume":"57","author":"Gabel","year":"2022","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.jcf.2024.09.022_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2023.05.010","article-title":"Nutritional considerations for a new era: a CF foundation position paper","author":"Leonard","year":"2023","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.jcf.2024.09.022_bib0023","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2466-6-9","article-title":"An adult cystic fibrosis patient presenting with persistent dyspnea: case report","volume":"6","author":"Onady","year":"2006","journal-title":"BMC. Pulm. Med."},{"issue":"Suppl 1","key":"10.1016\/j.jcf.2024.09.022_bib0024","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1258\/jrsm.2010.s11010","article-title":"Ischaemic heart disease\u2013a new issue in cystic fibrosis?","volume":"103","author":"Perrin","year":"2010","journal-title":"J. R. Soc. Med."},{"key":"10.1016\/j.jcf.2024.09.022_bib0025","article-title":"Coronary artery disease in patients with cystic fibrosis - a case series and review of the literature","volume":"30","author":"Sandouk","year":"2022","journal-title":"J. Clin. Transl. Endocrinol."},{"issue":"6","key":"10.1016\/j.jcf.2024.09.022_bib0026","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1016\/j.jcf.2016.09.010","article-title":"Coronary artery disease in cystic fibrosis: an emerging concern?","volume":"15","author":"Skolnik","year":"2016","journal-title":"J. Cyst. Fibros."},{"issue":"17","key":"10.1016\/j.jcf.2024.09.022_bib0027","first-page":"e484","volume":"138","author":"Whelton","year":"2018","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.jcf.2024.09.022_bib0028","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.kint.2020.10.026","article-title":"Executive summary of the KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease","volume":"99","author":"Cheung","year":"2021","journal-title":"Kidney Int."},{"issue":"9","key":"10.1016\/j.jcf.2024.09.022_bib0029","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.2337\/dc09-0586","article-title":"Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality","volume":"32","author":"Moran","year":"2009","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.jcf.2024.09.022_bib0030","doi-asserted-by":"crossref","first-page":"E1022","DOI":"10.1152\/ajpendo.2001.281.5.E1022","article-title":"Mechanisms of insulin resistance in cystic fibrosis","volume":"281","author":"Hardin","year":"2001","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"issue":"12","key":"10.1016\/j.jcf.2024.09.022_bib0031","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.2337\/dc10-1279","article-title":"Epidemiology, pathophysiology, and prognostic implications of cystic fibrosis-related diabetes: a technical review","volume":"33","author":"Moran","year":"2010","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.jcf.2024.09.022_bib0032","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.jcf.2019.01.009","article-title":"The main mechanism associated with progression of glucose intolerance in older patients with cystic fibrosis is insulin resistance and not reduced insulin secretion capacity","volume":"18","author":"Colomba","year":"2019","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.jcf.2024.09.022_bib0033","article-title":"Glycemia and beta-cell function before and after elexacaftor\/tezacaftor\/ivacaftor in youth and adults with cystic fibrosis","volume":"30","author":"Chan","year":"2022","journal-title":"J. Clin. Transl. Endocrinol."}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324017909?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324017909?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T22:11:34Z","timestamp":1738275094000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199324017909"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S1569199324017909"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2024.09.022","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of metabolic syndrome in people with Cystic Fibrosis one year after exposure to elexacaftor-tezacaftor-ivacaftor","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2024.09.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}